The text starts here.

News Release

FOR IMMEDIATE RELEASE
December 5, 2013

EISAI TO PRESENT NEW RESEARCH ON HALAVEN® (ERIBULIN)
AT 36TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, “Eisai”) announced today that new clinical study results on the company's novel anticancer agent Halaven® (eribulin mesylate) will be presented during the 2013 San Antonio Breast Cancer Symposium (SABCS). The symposium will be held from December 10 through 14, 2013, in San Antonio, Texas in the United States.

The studies reflect Eisai's current and ongoing research efforts to establish the clinical benefits of Halaven and maximize the drug's value. The studies to be presented at this year’s SABCS highlight the company's current oncology product portfolio strategy and research accomplishments in this field.

Eisai positions oncology as a key franchise area. The company will continue to create innovation in the development of new drugs based on cutting-edge cancer research in order to make further contributions to address the diversified needs of, and increase the benefits provided to, patients and their families as well as healthcare providers.

The following Eisai abstracts are accepted for presentation at this year's SABCS:
ProductAbstract name and scheduled presentation date and time (local time)
Halaven®
(eribulin mesylate)
Abstract no.:
P3-13-03
A phase III, open-label, randomized study of eribulin versus capecitabine in patients (pts) with metastatic breast cancer (MBC): Effect of post-progression anti-cancer treatments (PPT) and metastatic progression events on overall survival
Poster Session | December 12 (Thu), 17:00-19:00
Halaven®
(eribulin mesylate)
Abstract no.:
P3-13-04
Effect of age on tolerability and efficacy of eribulin and capecitabine in patients with metastatic breast cancer treated in study 301

Poster Session | December 12 (Thu), 17:00-19:00
Halaven®
(eribulin mesylate)
Abstract no.:
P3-13-05
Eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer: Results of a phase 2, multicenter, single-arm study

Poster Session | December 12 (Thu), 17:00-19:00
Halaven®
(eribulin mesylate)
Abstract no.:
P4-12-12
Phase 2, multicenter, single-arm study of eribulin mesylate + trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer

Poster Session | December 13 (Fri), 7:00-9:30

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120